Genocea Biosciences (NASDAQ:GNCA) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a research report issued on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Genocea Biosciences Stock Performance

Shares of NASDAQ GNCA opened at $0.00 on Monday. The stock has a market capitalization of $5,873.00, a PE ratio of 0.00 and a beta of 1.61. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a 52 week low of $0.00 and a 52 week high of $0.00.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.